IDSA and HIVMA are working with the National Coalition of STD Directors and Treatment Action Group to address supply and cost issues affecting the response to the growing STI epidemic. We are particularly concerned about access to Bicillin-LA, manufactured by Pfizer Inc, following a drug shortage in 2017 and the cost of the drug for providers without access to 340B.

Data showing a tripling of hepatitis C cases across America during the last decade highlight urgent and multi-faceted public health needs for expanded access to prevention, screening and treatment in addition to integrated health services that provide care for substance use disorders and associated infectious diseases.

The administration’s reported intention to redefine gender based entirely on sex at birth disregards not only current biologic science but also established, prevailing medical and legal standards, while re-enforcing stigma and discrimination against transgender people.